S&P 500   3,903.24 (+2.42%)
DOW   31,606.00 (+2.18%)
QQQ   322.11 (+2.54%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
S&P 500   3,903.24 (+2.42%)
DOW   31,606.00 (+2.18%)
QQQ   322.11 (+2.54%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
S&P 500   3,903.24 (+2.42%)
DOW   31,606.00 (+2.18%)
QQQ   322.11 (+2.54%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
S&P 500   3,903.24 (+2.42%)
DOW   31,606.00 (+2.18%)
QQQ   322.11 (+2.54%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
Log in
NASDAQ:CTRX

71098 Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume2.83 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

71098 (NASDAQ:CTRX) Vs. LH, DGX, DVA, AMED, CHE, and LHCG

Should you be buying CTRX stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to 71098, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), and LHC Group (LHCG).

Laboratory Co. of America (NYSE:LH) and 71098 (NASDAQ:CTRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Laboratory Co. of America and 71098's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.06$823.80 million$11.3221.60
71098N/AN/AN/AN/AN/A

Laboratory Co. of America has higher revenue and earnings than 71098.

Insider and Institutional Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Laboratory Co. of America and 71098, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
710980000N/A

Laboratory Co. of America presently has a consensus price target of $235.4667, indicating a potential downside of 4.32%.

Profitability

This table compares Laboratory Co. of America and 71098's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
71098N/AN/AN/A

Summary

Laboratory Co. of America beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 (NASDAQ:CTRX) and Quest Diagnostics (NYSE:DGX) are both companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares 71098 and Quest Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
71098N/AN/AN/AN/AN/A
Quest Diagnostics$7.73 billion2.02$858 million$6.5617.81

Quest Diagnostics has higher revenue and earnings than 71098.

Insider and Institutional Ownership

85.7% of Quest Diagnostics shares are held by institutional investors. 1.5% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for 71098 and Quest Diagnostics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
710980000N/A
Quest Diagnostics09602.40

Quest Diagnostics has a consensus target price of $129.00, indicating a potential upside of 8.87%.

Profitability

This table compares 71098 and Quest Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
71098N/AN/AN/A
Quest Diagnostics13.22%19.23%8.77%

Summary

Quest Diagnostics beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 (NASDAQ:CTRX) and DaVita (NYSE:DVA) are both companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares 71098 and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
71098N/AN/AN/A
DaVita7.32%43.99%5.27%

Analyst Recommendations

This is a breakdown of current ratings and price targets for 71098 and DaVita, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
710980000N/A
DaVita04102.20

DaVita has a consensus target price of $116.40, indicating a potential upside of 11.50%.

Earnings and Valuation

This table compares 71098 and DaVita's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
71098N/AN/AN/AN/AN/A
DaVita$11.39 billion1.00$810.98 million$5.4019.31

DaVita has higher revenue and earnings than 71098.

Insider and Institutional Ownership

91.7% of DaVita shares are held by institutional investors. 1.0% of DaVita shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

DaVita beats 71098 on 7 of the 7 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and 71098 (NASDAQ:CTRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Amedisys and 71098's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion4.32$126.83 million$4.4058.58
71098N/AN/AN/AN/AN/A

Amedisys has higher revenue and earnings than 71098.

Profitability

This table compares Amedisys and 71098's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
71098N/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Amedisys and 71098, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys03902.75
710980000N/A

Amedisys currently has a consensus target price of $274.4615, indicating a potential upside of 6.55%.

Insider & Institutional Ownership

85.9% of Amedisys shares are held by institutional investors. 2.8% of Amedisys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Amedisys beats 71098 on 7 of the 7 factors compared between the two stocks.

Chemed (NYSE:CHE) and 71098 (NASDAQ:CTRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Chemed and 71098's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$1.94 billion3.71$219.92 million$13.9532.32
71098N/AN/AN/AN/AN/A

Chemed has higher revenue and earnings than 71098.

Profitability

This table compares Chemed and 71098's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemed13.11%38.13%21.70%
71098N/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Chemed and 71098, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemed00203.00
710980000N/A

Chemed currently has a consensus price target of $557.50, indicating a potential upside of 23.43%.

Insider & Institutional Ownership

86.0% of Chemed shares are held by institutional investors. 4.0% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Chemed beats 71098 on 7 of the 7 factors compared between the two stocks.

71098 (NASDAQ:CTRX) and LHC Group (NASDAQ:LHCG) are both companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares 71098 and LHC Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
71098N/AN/AN/AN/AN/A
LHC Group$2.08 billion2.83$95.73 million$4.4741.68

LHC Group has higher revenue and earnings than 71098.

Profitability

This table compares 71098 and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
71098N/AN/AN/A
LHC Group5.00%9.71%6.51%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for 71098 and LHC Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
710980000N/A
LHC Group01702.88

LHC Group has a consensus target price of $227.7778, indicating a potential upside of 22.47%.

Insider & Institutional Ownership

91.8% of LHC Group shares are owned by institutional investors. 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

LHC Group beats 71098 on 7 of the 7 factors compared between the two stocks.


71098 Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$244.55flat$23.37 billion$11.55 billion28.47
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$116.85flat$15.43 billion$7.73 billion14.44
DaVita logo
DVA
DaVita
2.0$104.25flat$11.17 billion$11.39 billion15.63
Amedisys logo
AMED
Amedisys
1.2$257.75flat$8.32 billion$1.96 billion51.65Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Chemed logo
CHE
Chemed
2.3$450.93flat$7.10 billion$1.94 billion27.35Earnings Announcement
Ex-Dividend
LHC Group logo
LHCG
LHC Group
1.7$186.29flat$5.74 billion$2.08 billion56.62Earnings Announcement
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.3$76.02flat$3.43 billion$2.22 billion40.65Analyst Report
R1 RCM logo
RCM
R1 RCM
1.6$28.48flat$3.22 billion$1.19 billion316.48Gap Down
MEDNAX logo
MD
MEDNAX
1.4$24.68flat$2.09 billion$3.51 billion-2.86
The Providence Service logo
PRSC
The Providence Service
0.8$128.26flat$1.82 billion$1.51 billion-2,137.31
CorVel logo
CRVL
CorVel
0.8$103.65flat$1.81 billion$592.22 million46.07Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.0$23.77flat$1.16 billion$1.13 billion-2.15Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$11.71flat$417.33 million$822.22 million-22.52Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Down
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.7$3.25flat$13.18 million$24.08 million-0.38Increase in Short Interest
Gap Down
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.